Musculoskeletal system pathology: substantiation of the possibility of undenaturated collagen type ii including in complex treatment of knee joints osteoarthritis


DOI: https://dx.doi.org/10.18565/therapy.2019.6.190-197

Dydykina I.S., Nurbaeva K.S., Kovalenko P.S., Zotkin E.G.

V.A. Nasonova scientific research institute of rheumatology, Moscow
The article discusses the widespread prevalence of musculoskeletal system diseases (BCMS), the occurrence and course of which is accompanied by inflammation and pain. Attention is drawn to the fact that many diseases, including osteoarthritis, are getting «younger», while the proportion of older people, who make up the majority of patients, is steadily increasing.
Use of traditional analgesics, non-steroidal anti-inflammatory drugs in elderly patients is limited or contraindicated in cases of a high risk of cardiovascular complications, chronic renal disease, stomach ulcer or gastrointestinal bleeding in anamnesis, bronchial asthma, etc. Local drugs and/or alternative pain relievers (slow-acting symptom-modifying drugs, analgesics with a central mechanism of action etc.) should be prescribed to this category of patients.
Expanding the arsenal of remedies for the prevention and treatment of osteoarthritis with proven efficacy and safety is of great practical importance. Separately, the article considers the mechanism of action, provements of efficacy and safety of undenaturated collagen type 2 (Sustaflex) and the possibility of its use in the treatment of knee joint osteoarthritis.
Keywords: type 2 undenatured collagen (Sustaflex), treatment of pain in case of gonarthrosis, musculoskeletal system diseases, osteoarthritis
Read entire article

Literature


  1. Эрдес Ш.Ф., Дубинина Т.В., Галушко Е.А. Боли в нижней части спины в общеклинической практике. Терапевтический архив. 2008; 80(5): 59–61.

  2. Friedly J., Standaert C., Chan L. Epidemiology of spine care: the back pain dilemma. Phys Med Rehabil Clin N Am. 2010; 21(4): 659–77. doi: 10.1016/j.pmr.2010.08.00.

  3. Litwic A., Edwards M., Dennison E., Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013; 105: 185–99. doi: 10.1093/bmb/lds038 15.

  4. Zhang Y., Jordan J. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010; 26(3): 355–69. doi: 10.1016/j.cger.2010.03.001.

  5. Murphy L., Helmick C. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs. 2012; 112(3 Suppl 1): 13–19. doi: 10.1097/01.NAJ.0000412646.80054.21.

  6. Millar N.L., Murrell G.A., McInnes I.B. Alarmins in tendinopathy: unravelling new mechanisms in a common disease. Rheumatology (Oxford). 2013 May; 52(5): 769–79. doi: 10.1093/rheumatology/kes409. Epub 2013 Jan 28.

  7. Диагностика и лечение боли. Под ред. Дж. Х. Ван Роенн, Дж.А. Пэйс, М.И. Преодер. М.: БИНОМ. 2012; 496 с.

  8. http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/

  9. Распоряжение Правительства Российской Федерации от 5 февраля 2016 г. № 164-р «Стратегия действий в интересах граждан старшего поколения в Российской Федерации до 2025 года».

  10. Боль (практическое руководство для врачей). Под ред. Н.Н. Яхно, М.Л. Кукушкина. М.: Издательство РАМН. 2012; 512 c.

  11. Кукушкин М.Л., Табеева Г.Р., Подчуфарова Е.В. Болевой синдром: патофизиология, клиника, лечение. М.: ИМАПРЕСС. 2011; 72 с.

  12. Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова, М.: ГЭОТАР-Медиа. 2017; 464 с. ISBN 978-5-9704-4261-6.

  13. Standardization of Osteoarthritis Definitions, Osteoarthritis Research Society International. https://www.oarsi.org/research/standardizationosteoarthritis-definitions [accessed: 04-06-2017].

  14. Фоломеева О.М., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно-практическая ревматология. 2008; 4: 4–12.

  15. Guccione A.A., Felson D.T., Anderson J.J. et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am. J. Public. Health. 1994; 84: 351–58.

  16. Балабанова Р.М., Дубинина Т.В., Демина А.Б., Кричевская О.А.. Заболеваемость болезнями костно-мышечной системы в Российской Федерации в 2015- 2016 гг. Научно-практическая ревматология. 2018; 56(1): 15–21.

  17. Bruyere O., Cooper C., Pelletier J. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum 2014; 2–11. doi:10.1016/j.semarthrit.2014.05.014.

  18. Bruyere O., Honvo G., Veronese N., Arden N.K., Branco J., Curtis E.M., Al-Daghri N.M., Herrero-Beaumont G., Martel-Pelletier J., Pelletier J.P., Rannou F., Rizzoli R., Roth R., Uebelhart D., Cooper C., Reginster J.Y. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO)Semin Arthritis Rheum. 2019 Apr 30; pii: S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008.

  19. Leopoldino A.O., Machado G.C., Ferreira P.H., Pinheiro M.B., Day R., McLachlan A.J., Hunter D.J., Ferreira M.L. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database of Systematic Reviews. 2019; 2. Art. No.: CD013273. doi: 10.1002/14651858.CD013273.

  20. Towheed T.E., Maxwell L., Anastassiades T.P., Shea B., Houpt J., Welch V. et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2009; 2: CD002946.

  21. Singh J.A., Noorbaloochi S., MacDonald R., Maxwell L.J. Chondroitin for osteoarthritis. Cochrane Database of Systematic Reviews. 2015 Jan 28; 1: CD005614. doi: 10.1002/14651858.CD005614.pub2.

  22. Committee on toxicity of chemicals in food, consumer products and the environment. COT statement 2009/01. http://cot.food.gov.uk/pdfs/cotstatementgluco200901.pdf (15.01.10).

  23. Schauss A.G., Merkel D.J., Glaza S.M., Sorenson S.R. Acute and subchronic oral toxicity studies in rats of a hydrolyzed chicken sternal cartilage preparation. Food Chem Toxicol. 2007; 45(2): 315–21.

  24. Xin W., Heilig J., Paulsson M., Zaucke F. Collagen II regulates chondrocyte integrin expression profile and differentiation. Connect. Tissue Res. 2015; 56: 307–14.

  25. Kannu P., Bateman J., Savarirayan R. J Paediatr Child Health. 2012 Feb; 48(2): E38–43. doi: 10.1111/j.1440-1754.2010.01979.x.

  26. Eyre D. Collagen of articular cartilage. Arthritis Res. 2002; 4(1): 30–35. doi:10.1186/ar380.

  27. Charni-Ben Tabassi N., Desmarais S., Bay-Jensen A.C., Delaisse J.M., Percival M.D., Garnero P. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage. 2008 Oct; 16(10): 1183–91.

  28. Faria, A.M., Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 2006; 13: 143–57.

  29. Commins S.P. Mechanisms of oral tolerance. Pediatr Clin North Am. 2015; 62(6): 1523–29. doi:10.1016/j.pcl.2015.07.013.

  30. Ram Prabhoo, Gauri Billa. Undenatured collagen type II for the treatment of osteoarthritis: a review, International Journal of Research in Orthopaedics, Prabhoo R. et al. Int J Res Orthop. 2018 Sep; 4(5): 684–89.

  31. Bagi C.M., Berryman ER, Teo S, Lane NE. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). Osteoarthritis and Cartilage. 2017; 25: 2080–90.

  32. Di Cesare Mannelli L., Micheli L., Zanardelli M,. Ghelardini C. Low dose native type II collagen prevents pain in a rat osteoarthritis model. BMC Musculoskeletal Disorders. 2013; 14: 228.

  33. Lugo J.P., Saiyed Z.M., Lau F.C., Molina J.P.L., Pakdaman M.N., Shamie A.N. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Society Sports Nutr. 2013; 10: 48.

  34. Crowley D.C., Lau F.C., Sharma P., Evans M., Guthrie N., Bagchi M. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009; 6: 312–21.

  35. Lugo J.P., Saiyed Z.M., Lane N.E. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutrition J. 2016; 15: 14.


About the Autors

Irina S. Dydykina, PhD, leading researcher of the laboratory for monitoring the safety of anti-rheumatic drugs of V.A. Nasonova scientific research institute of rheumatology. Address: 115522, Moscow, 34-A Kashirskoye Shosse Str. Tel.: +7 (903) 763-21-98. E-mail: dydykina_is@mail.ru
Kamila S. Nurbaeva, clinical resident of V.A. Nasonova scientific research institute of rheumatology. Address: 115522, Moscow, 34-A Kashirskoye Shosse Str. Tel.: +7 (925) 350-75-69. E-mail: camila9@mail.ru
Polina S. Kovalenko, PhD, junior researcher of the Department of metabolic diseases of bones and joints with the center of osteoporosis prevention of V.A. Nasonova scientific research institute of rheumatology. Address: 115522, Moscow, 34-A Kashirskoye Shosse Str. E-mail: polina_dydykina@mail.ru
Evgeny G. Zotkin, MD, first deputy director of V.A. Nasonova scientific research institute of rheumatology. Address: 115522, Moscow, 34-A Kashirskoye Shosse Str. E-mail: ezotkin@mail.ru


Similar Articles

Back to Content

Бионика Медиа